One case of scleroderma-like skin in bilateral calves induced by pemetrexed disodium for injection

doi:10.19803/j.1672-8629.20230157

Abstract

Abstract: Objective To explore the clinical characteristics and treatment of adverse reactions in the skin of lower limbs caused by pemetrexed. Methods One case of rare skin toxicity in the lower leg caused by pemetrexed disodium for injection in a patient with non-small cell lung cancer was analyzed. The clinical manifestations and appropriate treatments of such rare skin toxicity were summarized based on literature review. Results The clinical manifestations of this patient, including swelling, erythema multiforme, itching, pigmentation, pain, sclerosis, and fever, were similar to those of pemetrexed related sclerodermic changes reported abroad, and the use of antibacterial drugs had no significant effect. After the dose of pemetrexed chemotherapy was reduced and hormone and antihistamine drugs for symptomatic treatment were used, the symptoms were significantly alleviated. Conclusion The sclerodermic changes related to pemetrexed are not included in the known adverse reactions of pemetrexed and are often misdiagnosed as cellulitis or erysipelas, which can seriously affect the quality of life of patients and deserves attention.

Key words: injection, pemetrexed, lower extremity, skin, adverse drug reaction, non-small cell lung cancer

CLC Number:

LIANG Yan, YAN Jiaqing, YANG Jun. One case of scleroderma-like skin in bilateral calves induced by pemetrexed disodium for injection[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1293-1295.

References

[1] LOPES G, VINCEK V, RAEZ L.Pemetrexed associated urticarial vasculitis[J]. Lung Cancer, 2006, 51: 247-249.
[2] D’ANGELO SP, KRIS MG, PIETANZA MC, et al. A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed[J]. J ThoracOncol, 2011, 6(3): 624-626.
[3] VOGELZANG NJ, RUSTHOVEN JJ, SYMANOWSKI J, et al.Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J]. J ClinOncol, 2003, 21(14): 2636-2644.
[4] FOSSELLA FV, GATZEMEIER U.Phase I trials of pemetrexed[J]. Semin Oncol, 2002, 29(Suppl 5): 8-16.
[5] HAZARIKA M, WHITE RM JR, BOOTH BP, et al.Pemetrexed in malignant pleural mesothelioma[J]. Clin Cancer Res, 2005, 11(3): 982-992.
[6] SHUSTER M, MORLEY K, LOGAN J, et al.Lipodermatosclerosis secondary to pemetrexed use[J]. J ThoracOncol, 2015, 10(3): e11-e12.
[7] VITIELLO M, ROMANELLI P, KERDEL FA.Painful generalized erythematous patches: a severe and unusual cutaneous reaction to pemetrexed[J]. J Am AcadDermatol, 2011, 65: 243-244.
[8] EGUIA B, RUPPERT AM, FILLON J, et al.Skin toxicities compromise prolonged pemetrexed treatment[J]. J ThoracOncol, 2011, 6: 2083-2089.
[9] MERKLEN-DJAFRI C, IMBERT E, COUROUGE-DORCIER D, et al.Pemetrexed induced skin sclerosis[J]. ClinOncol, 2012, 24: 452-453.
[10] CORBAUX C, MARIE J, MERAUD JP, et al.Pemetrexed-induced scleroderma-like changes in the lower legs[J]. Ann DermatolVenereol, 2015, 142: 115-120.
[11] ISHIKAWA K, SAKAI T, SAITO-SHONO T, et al.Pemetrexed-induced scleroderma-like conditions in the lower legs of a patient with non-small cell lung carcinoma[J]. J Dermatol, 2016, 43(9): 1071-1074.
[12] Center for Drug Reevaluation. Provisions for Adverse Drug Reaction Reporting and Monitoring(药品不良反应报告和监测管理办法培训教材)[M]. Beijing: China Medical Science and Press, 2012.
[13] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[14] PIÉRARD-FRANCHIMONT C, QUATRESOOZ P, REGINSTER MA, et al. Revisiting cutaneous adverse reactions to pemetrexed[J]. Oncol Lett, 2011, 2(5): 769-772.
[15] HAUSTEIN UF, HAUPT B.Drug-induced scleroderma and sclerodermiform conditions[J]. ClinDermatol, 1998, 16(3): 353-366.
[16] TRACEY EH, MODI B, MICHELETTI RG.Pemetrexed-induced pseudocellulitis reaction with eosinophilic infiltrate on skin biopsy[J]. Am J Dermatopathol, 2017, 39(1): e1-e2.
[17] DEBIEN V, PETITDEMANGE A, BAZIN D, et al . New-onset systemic sclerosis and scleroderma renal crisis under docetaxel[J]. J Scleroderma Relat Disord, 2021, 6(3): 306-310.
[18] HAMAGUCHI Y.Drug-induced scleroderma-like lesion[J]. Allergol Int, 2022, 71(2): 163-168.